The wide use of next-generation sequencing has allowed professionals to reach relevant progress in the medical field including diagnoses, prognoses, and genetic counselling and to help in recognizing the pathogenic mechanisms which underlie several epileptic disorders. Genetic epilepsy refers to a disorder in which genetic mutations are recognized as the primary cause of epileptic seizures in the patients. Various types of epilepsy have been highlighted alongside a clear etiologic relationship with genetic mutations; however, for a select number of patients, some doubts remain on the role played by the variant mutations, as well as the adverse pathologic events which may interfere with the clinical manifestations. In this study, twenty-seven children affected by epileptic seizures are reported, with the aim to describe the clinical and neurological involvement presented by the children according to the genes and variant mutations, and to compare the neurological signs observed in these children with those reported in children with similar genetic mutations. Additionally, the roles played by single or associated variants on the clinical expression of the affected children are discussed.
A retrospective observational study was conducted on the gene mutations observed in 27 children affected by a clinical history and diagnosis of epilepsy, alongside an electroencephalographic analysis performed with the Pediatric Department of the University-Hospital S. Marco during the years ranging from January 2020 to January 2022. A genetic analysis was performed using an array comparative genomic hybridization (array CGH), a gene panel for epilepsy, Whole Exome Sequencing (WES), and a single nucleotide polymorphism (SNP) array.
Nineteen children showed a single nucleotide variant, eight children carried two or more gene mutations in different genes, and one child was not reported. In this study, we identified a total of thirty-six gene mutations, where seventeen were de novo mutations, and twenty-two had either a maternal or paternal inheritance. The genes in which one or more allelic variants were found included GRIN2A, GABRA1, SCN2A1, KCNT1, PCDH19, SCN8A, KCNK4, SLC2A1, DNM1, ARID1B, WWOX, GABRG2, and others.
Genetic analyses are recognized to have a central role in the diagnostic process of children with epileptic seizures, alongside their family history, and clinical, neuroradiologic, and neurophysiologic examinations. The gene mutation anomalies reported in this study may be useful to be included in the wide field of factors related to epileptic seizures in children. The roles played by single or associated variant mutations in the clinical expression of the affected epileptic children remain difficult to be defined. Moreover, other factors such as pre-, peri-, and post-natal adverse events may negatively interfere with the severity of the clinical manifestations.
Citation: Piero Pavone, Ottavia Avola, Claudia Oliva, Alessandra Di Nora, Tiziana Timpanaro, Chiara Nannola, Filippo Greco, Raffaele Falsaperla, Agata Polizzi. Genetic epilepsy and role of mutation variants in 27 epileptic children: results from a “single tertiary centre” and literature review[J]. AIMS Medical Science, 2024, 11(3): 330-347. doi: 10.3934/medsci.2024023
The wide use of next-generation sequencing has allowed professionals to reach relevant progress in the medical field including diagnoses, prognoses, and genetic counselling and to help in recognizing the pathogenic mechanisms which underlie several epileptic disorders. Genetic epilepsy refers to a disorder in which genetic mutations are recognized as the primary cause of epileptic seizures in the patients. Various types of epilepsy have been highlighted alongside a clear etiologic relationship with genetic mutations; however, for a select number of patients, some doubts remain on the role played by the variant mutations, as well as the adverse pathologic events which may interfere with the clinical manifestations. In this study, twenty-seven children affected by epileptic seizures are reported, with the aim to describe the clinical and neurological involvement presented by the children according to the genes and variant mutations, and to compare the neurological signs observed in these children with those reported in children with similar genetic mutations. Additionally, the roles played by single or associated variants on the clinical expression of the affected children are discussed.
A retrospective observational study was conducted on the gene mutations observed in 27 children affected by a clinical history and diagnosis of epilepsy, alongside an electroencephalographic analysis performed with the Pediatric Department of the University-Hospital S. Marco during the years ranging from January 2020 to January 2022. A genetic analysis was performed using an array comparative genomic hybridization (array CGH), a gene panel for epilepsy, Whole Exome Sequencing (WES), and a single nucleotide polymorphism (SNP) array.
Nineteen children showed a single nucleotide variant, eight children carried two or more gene mutations in different genes, and one child was not reported. In this study, we identified a total of thirty-six gene mutations, where seventeen were de novo mutations, and twenty-two had either a maternal or paternal inheritance. The genes in which one or more allelic variants were found included GRIN2A, GABRA1, SCN2A1, KCNT1, PCDH19, SCN8A, KCNK4, SLC2A1, DNM1, ARID1B, WWOX, GABRG2, and others.
Genetic analyses are recognized to have a central role in the diagnostic process of children with epileptic seizures, alongside their family history, and clinical, neuroradiologic, and neurophysiologic examinations. The gene mutation anomalies reported in this study may be useful to be included in the wide field of factors related to epileptic seizures in children. The roles played by single or associated variant mutations in the clinical expression of the affected epileptic children remain difficult to be defined. Moreover, other factors such as pre-, peri-, and post-natal adverse events may negatively interfere with the severity of the clinical manifestations.
[1] | Thomas RH, Berkovic SF (2014) The hidden genetics of epilepsy—a clinically important new paradigm. Nat Rev Neurol 10: 283-292. https://doi.org/10.1038/nrneurol.2014.62 |
[2] | McTague A, Howell KB, Cross JH, et al. (2016) The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 15: 304-316. https://doi.org/10.1016/S1474-4422(15)00250-1 |
[3] | Claes L, Del-Favero J, Ceulemans B, et al. (2001) De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68: 1327-1332. https://doi.org/10.1086/320609 |
[4] | Carvill GL, Heavin SB, Yendle SC, et al. (2013) Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 45: 825-830. https://doi.org/10.1038/ng.2646 |
[5] | Moller RS, Larsen LH, Johannesen KM, et al. (2016) Gene panel testing in epileptic encephalopathies and familial epilepsies. Mol Syndromol 7: 210-219. https://doi.org/10.1159/000448369 |
[6] | Lindy AS, Stosser MB, Butler E, et al. (2018) Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia 59: 1062-1071. https://doi.org/10.1111/epi.14074 |
[7] | Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. (2015) Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 56: 707-716. https://doi.org/10.1111/epi.12954 |
[8] | Ortega-Moreno L, Giraldez BG, Soto-Insuga V, et al. (2017) Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. PLoS One 12: e0188978. https://doi.org/10.1371/journal.pone.0188978 |
[9] | Snoeijen-Schouwenaars FM, van Ool JS, Verhoeven JS, et al. (2019) Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability. Epilepsia 60: 155-164. https://doi.org/10.1111/epi.14618 |
[10] | Costain G, Cordeiro D, Matviychuk D, et al. (2019) Clinical application of targeted next-generation sequencing panels and whole exome sequencing in childhood epilepsy. Neuroscience 418: 291-310. https://doi.org/10.1016/j.neuroscience.2019.08.016 |
[11] | Helbig KL, Farwell Hagman KD, Shinde DN, et al. (2016) Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med 18: 898-905. https://doi.org/10.1038/gim.2015.186 |
[12] | Moller RS, Hammer TB, Rubboli G, et al. (2019) From next-generation sequencing to targeted treatment of non-acquired epilepsies. Expert Rev Mol Diagn 19: 217-228. https://doi.org/10.1080/14737159.2019.1573144 |
[13] | Mefford H, Muhle H, Ostertag P, et al. (2010) Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet 6: e1000962. https://doi.org/10.1371/journal.pgen.1000962 |
[14] | Hauser WA, Annegers JF, Rocco WA (1996) Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71: 576-586. https://doi.org/10.4065/71.6.576 |
[15] | Mangano GD, Riva A, Fontana A, et al. (2022) De novo GRIN2A variants associated with epilepsy and autism and literature review. Epilepsy Behav 129: 108604. https://doi.org/10.1016/j.yebeh.2022.108604 |
[16] | Strehlow V, Heyne HO, Vlaskamp DRM, et al. (2019) GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain 142: 80-92. https://doi.org/10.1093/brain/awy304 |
[17] | Johannesen K, Marini C, Pfeffer S, et al. (2016) Phenotypic spectrum of GABRA1: from generalized epilepsies to severe epileptic encephalopathies. Neurology 87: 1140-1151. https://doi.org/10.1212/WNL.0000000000003087 |
[18] | Kodera H, Ohba C, Kato M, et al. (2016) De novo GABRA1 mutations in Ohtahara and West syndromes. Epilepsia 57: 566-573. https://doi.org/10.1111/epi.13344 |
[19] | Kim HJ, Yang D, Kim SH, et al. (2020) The phenotype and treatment of SCN2A-related developmental and epileptic encephalopathy. Epileptic Disord 22: 563-570. https://doi.org/10.1684/epd.2020.1199 |
[20] | Melikishvili G, Dulac O, Gataullina S (2020) Neonatal SCN2A encephalopathy: a peculiar recognizable electroclinical sequence. Epilepsy Behav 111: 107187. https://doi.org/10.1016/j.yebeh.2020.107187 |
[21] | Penkl A, Reunert J, Debus OM, et al. (2022) A mutation in the neonatal isoform of SCN2A causes neonatal-onset epilepsy. Am J Med Genet A 188: 941-947. https://doi.org/10.1002/ajmg.a.62581 |
[22] | Zeng Q, Yang Y, Duan J, et al. (2022) SCN2A-related epilepsy: the phenotypic spectrum, treatment and prognosis. Front Mol Neurosci 15: 809951. https://doi.org/10.3389/fnmol.2022.809951 |
[23] | Gertler T, Bearden D, Bhattacharjee A, et al. (2018) KCNT1-related Epilepsy. University of Washington, Seattle: GeneReviews®. |
[24] | Bonardi CM, Heyne HO, Fiannacca M, et al. (2021) KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum. Brain 144: 3635-3650. https://doi.org/10.1093/brain/awab219 |
[25] | Borlot F, Abushama A, Morrison-Levy N, et al. (2020) KCNT1-related epilepsy: an international multicenter cohort of 27 pediatric cases. Epilepsia 61: 679-692. https://doi.org/10.1111/epi.16480 |
[26] | Samanta D (2028) PCDH19-related epilepsy syndrome: a comprehensive clinical review. Pediatr Neurol 105: 3-9. https://doi.org/10.1016/j.pediatrneurol.2019.10.009 |
[27] | Smith L, Singhal N, Achkar CM, et al. (2018) PCDH19-related epilepsy is associated with a broad neurodevelopmental spectrum. Epilepsia 59: 679-689. https://doi.org/10.1111/epi.14003 |
[28] | Trivisano M, Specchio N (2019) The role of PCDH19 in refractory status epilepticus. Epilepsy Behav 101: 106539. https://doi.org/10.1016/j.yebeh.2019.106539 |
[29] | Kolc KL, Møller RS, Sadleir LG, et al. (2020) PCDH19 pathogenic variants in males: expanding the phenotypic spectrum. Adv Exp Med Biol 1298: 177-187. https://doi.org/10.1007/5584_2020_574 |
[30] | Johannesen KM, Liu Y, Koko M, et al. (2022) Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain 145: 2991-3009. https://doi.org/10.1093/brain/awab321 |
[31] | Gardella E, Møller RS (2019) Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia 60: S77-S85. https://doi.org/10.1111/epi.16319 |
[32] | Talwar D, Hammer MF (2021) SCN8A epilepsy, developmental encephalopathy, and related disorders. Pediatr Neurol 122: 76-83. https://doi.org/10.1016/j.pediatrneurol.2021.06.011 |
[33] | Bauer CK, Calligari P, Radio FC, et al. (2018) Mutations in KCNK4 that affect gating cause a recognizable neurodevelopmental syndrome. Am J Hum Genet 103: 621-630. https://doi.org/10.1016/j.ajhg.2018.09.001 |
[34] | Hamilton MJ, Suri M (2020) “Electrifying dysmorphology”: potassium channelopathies causing dysmorphic syndromes. Adv Genet 105: 137-174. https://doi.org/10.1016/bs.adgen.2020.03.002 |
[35] | Koch H, Weber YG (2019) The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav 91: 90-93. https://doi.org/10.1016/j.yebeh.2018.06.010 |
[36] | Legido MJ, Ledesma CC, Cuesta BB, et al. (2022) Study of paediatric patients with the clinical and biochemical phenotype of glucose transporter type 1 deficiency syndrome. Neurologia 37: 91-100. https://doi.org/10.1016/j.nrl.2018.10.006 |
[37] | von Spiczak S, Helbig KL, Shinde DN, et al. (2017) DNM1 encephalopathy: a new disease of vesicle fission. Neurology 89: 385-394. https://doi.org/10.1212/WNL.0000000000004152 |
[38] | Choi E, Dale B, RamachandranNair R, et al. (2021) Pathogenic DNM1 gene variant presenting with unusually non severe neurodevelopmental phenotype: a case report. Neurol Genet 7: e618. https://doi.org/10.1212/NXG.0000000000000618 |
[39] | Vergano SA, van der Sluijs PJ, Santen G (2019) ARID1B-Related Disorder. University of Washington, Seattle: GeneReviews® [Internet]. |
[40] | Proietti J, Amadori E, Striano P, et al. (2021) Epilepsy features in ARID1B-related Coffin-Siris syndrome. Epileptic Disord 23: 865-874. https://doi.org/10.1684/epd.2021.1356 |
[41] | Banne E, Abudiab B, Abu-Swai S, et al. (2021) Neurological disorders associated with WWOX germline mutations—a comprehensive overview. Cells 10: 824. https://doi.org/10.3390/cells10040824 |
[42] | Aldaz CM, Hussain T (2020) WWOX loss of function in neurodevelopmental and neurodegenerative disorders. Int J Mol Sci 21: 8922. https://doi.org/10.3390/ijms21238922 |
[43] | Kang JQ, Macdonald RL (2016) Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. JAMA Neurol 73: 1009-1016. https://doi.org/10.1001/jamaneurol.2016.0449 |
[44] | Polizzi A, Incorpora G, Pavone P, et al. (2012) Generalized epilepsy with febrile seizures plus (GEFS (+)): molecular analysis in a restricted area. Childs Nerv Syst 28: 141-145. https://doi.org/10.1007/s00381-011-1592-9 |